Author

Gus Alva

Observed names: G Alva, G. Alva

Institutions: University of California, Riverside, ATP Clinical Research (United States)

Observed institutions: University of California, Riverside, Brigham and Women's Hospital, University of Pittsburgh, Pfizer (United States), University of Toronto, Pfizer (United Kingdom), University of California, Irvine, University of Michigan, ATP Clinical Research (United States), UCL Queen Square Institute of Neurology, Janssen Alzheimer Immunotherapy Research & Development (United States), University College London

OpenAlex ID: A5111762880

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

2000 · V S Basile, V Özdemir, et al. · Molecular Psychiatry · 168

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

2015 · Enchi Liu, Mark E. Schmidt, et al. · Neurology · 151

PDF

Therapeutic Effects of Individualized Alpha Frequency Transcranial Magnetic Stimulation ( TMS) on the Negative Symptoms of Schizophrenia

2005 · Y. Jin, S. G. Potkin, et al. · Schizophrenia Bulletin · 141

PDF

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine

2003 · S G Potkin, V S Basile, et al. · Molecular Psychiatry · 113

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

2009 · Martin R. Farlow, Gus Alva, et al. · Current Medical Research and Opinion · 60

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

2018 · Enchi Liu, Dai Wang, et al. · Neurology · 44

PDF

Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

2015 · G. Alva, J. L. Cummings, et al. · International Journal of Clinical Practice · 22

PDF

A Pilot Study Evaluating the Efficacy and Safety of Rivastigmine in Patients with Mixed Dementia

2006 · Steven G Potkin, Gus Alva, et al. · Drugs & Aging · 21

A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia

2014 · Peter J. Weiden, Leslie Citrome, et al. · Schizophrenia Research · 18

Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study

2024 · Gus Alva, Wiesław J. Cubała, et al. · Journal of Alzheimer s Disease · 13

PDF

Switching to Iloperidone

2014 · Leslie Citrome, Peter J. Weiden, et al. · Clinical Schizophrenia & Related Psychoses · 8

Hierarchical Bayesian cognitive processing models to analyze clinical trial data

2012 · William R. Shankle, Junko Hara, et al. · Alzheimer s & Dementia · 7

EEG-guided RTMS improves negative symptoms in schizophrenia

2003 · Y. Jin, S.G. Potkin, et al. · Schizophrenia Research · 2

Predicting Clinical Antipsychotic Doses from Preclinical and PET studies: A Case Study with Asenapine

2003 · Steven G. Potkin, G. Alva, et al. · 1

Dosing, Patterns, Effectiveness, and Treatment Satisfaction with Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

2024 · Andrew J. Cutler, Gus Alva, et al. · CNS Spectrums

PDF

P3‐452: Bayesian cognitive models increase sensitivity for detecting treatment effect: Analysis of Flurizan phase III trial data

2010 · William R. Shankle, Gus Alva, et al. · Alzheimer s & Dementia

SWAP: the safety and tolerability of switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease

2009 · G Alva, M Farlow, et al. · Aktuelle Neurologie

P4.023 Memantine monotherapt increase brainmetabolism (PET) and effectively treats mild to moderate Alzheimer's disease

2004 · S.G. Potkin, S. McDonald, et al. · European Neuropsychopharmacology

Pharmacogenetics of antipsychotic induced weight gain and tardive dyskinesia

2000 · Vincenzo S. Basile, Mario Masellis, et al. · American Journal of Medical Genetics Part B Neuropsychiatric Genetics

Works count: 19

Citation count: 769

H-index: 10

I10-index: 10